Sunitinib-induced severe hypothyroidism with cardiac compromise.
Tyrosine kinase inhibitors (TKI) are an increasingly used class of anti-cancer agent. Sunitinib (sutent(®), Pfizer™, New York) is standard first-line therapy for patients with metastatic renal cancer. It is associated with a number of toxicities, including thyroid dysfunction. We present a case of sunitinib-induced severe hypothyroidism resulting in cardiac compromise. The case highlights the importance of interval thyroid function monitoring for patients on drugs, such as sunitinib and other TKIs.
St James's Institute of Oncology, Bexley Wing, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Fiona J
FJ
Collinson
Naveen S
NS
Vasudev
Liz
L
Berkin
Mohammed M
MM
Khan
Peter J
PJ
Selby
Janet E
JE
Brown
D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced* / Q000175:diagnosis*; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*; D012720:Severity of Illness Index; D000077210:Sunitinib
D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib